GAMMA Investing LLC Boosts Stock Position in Pulse Biosciences, Inc (NASDAQ:PLSE)

GAMMA Investing LLC increased its holdings in Pulse Biosciences, Inc (NASDAQ:PLSE) by 2,203.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,034 shares of the company’s stock after buying an additional 5,772 shares during the period. GAMMA Investing LLC’s holdings in Pulse Biosciences were worth $97,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Oppenheimer & Co. Inc. bought a new position in Pulse Biosciences in the fourth quarter valued at $311,000. Vanguard Group Inc. increased its stake in Pulse Biosciences by 15.1% in the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company’s stock valued at $19,958,000 after acquiring an additional 150,506 shares during the last quarter. Deutsche Bank AG increased its stake in Pulse Biosciences by 65.1% in the fourth quarter. Deutsche Bank AG now owns 16,795 shares of the company’s stock valued at $292,000 after acquiring an additional 6,625 shares during the last quarter. Barclays PLC increased its stake in Pulse Biosciences by 8.5% in the fourth quarter. Barclays PLC now owns 32,881 shares of the company’s stock valued at $573,000 after acquiring an additional 2,575 shares during the last quarter. Finally, Norges Bank bought a new position in Pulse Biosciences in the fourth quarter valued at $348,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Pulse Biosciences to a “sell” rating in a research note on Monday, March 31st.

Pulse Biosciences Stock Down 0.6%

Pulse Biosciences stock opened at $15.40 on Wednesday. The stock’s 50 day simple moving average is $16.91 and its two-hundred day simple moving average is $17.68. Pulse Biosciences, Inc has a fifty-two week low of $9.70 and a fifty-two week high of $25.00.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter.

Insider Activity

In other Pulse Biosciences news, CTO Darrin Uecker sold 15,000 shares of the firm’s stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $16.40, for a total transaction of $246,000.00. Following the sale, the chief technology officer now directly owns 137,872 shares of the company’s stock, valued at $2,261,100.80. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 71.50% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.